Arrow-right Camera
The Spokesman-Review Newspaper

The Spokesman-Review Newspaper The Spokesman-Review

Spokane, Washington  Est. May 19, 1883
Cloudy 53° Cloudy

Tag search results

Tags let us describe our content with keywords, making it easier to find what you're most interested in. Use the search box to look for tags, or explore our coverage with the lists below.

Big changes in White House ideas to pay for $2 trillion plan

SCRANTON, Pa. — In an abrupt change, the White House on Wednesday floated new plans to pay for parts of President Joe Biden’s $2 trillion social services and climate change package, shelving a proposed big increase in corporate tax rates though also adding a new billionaires' tax on the investment gains of the very richest Americans.

In budget turning point, Biden conceding smaller price tag

WASHINGTON — President Joe Biden and congressional Democrats' push for a 10-year, $3.5 trillion package of social and environmental initiatives has reached a turning point, with the president repeatedly conceding that the measure will be considerably smaller and pivotal lawmakers flashing potential signs of flexibility.

Panel OKs Dems’ $3.5T bill, crunch time for Biden agenda

WASHINGTON – Democrats pushed a $3.5 trillion, 10-year bill strengthening social safety net and climate programs through the House Budget Committee on Saturday, but one Democrat opposed the measure in an illustration of the challenges party leaders face in getting the near unanimity they’ll need to push the sprawling package through Congress.

Providers challenge only U.S. law banning vaccine mandates

HELENA – Medical providers and Montana residents with compromised immune systems are challenging the only law in the U.S. that prevents employers from mandating workers get vaccinated amid a surge of COVID-19 infections.

Democrats tackling flash points of taxes, health, climate

WASHINGTON – Revamp the tax code and important federal health care and environment programs. Spend $3.5 trillion over 10 years, but maybe a lot less. Ensure that no more than three Democrats in all of Congress vote “no” because Republicans will be unanimously opposed.

Sweeping new vaccine mandates for 100 million Americans

WASHINGTON — In his most forceful pandemic actions and words, President Joe Biden on Thursday ordered sweeping new federal vaccine requirements for as many as 100 million Americans — private-sector employees as well as health care workers and federal contractors — in an all-out effort to curb the surging COVID-19 delta variant.

Medicare evaluating coverage for $56,000 Alzheimer’s drug

WASHINGTON – Medicare on Monday launched a formal process to decide whether to cover Aduhelm, the new Alzheimer’s drug whose $56,000-a-year price tag and unproven benefits have prompted widespread criticism and a congressional investigation.

Dems eye $6T plan on infrastructure, Medicare, immigration

WASHINGTON — Democrats are eyeing a $6 trillion infrastructure investment plan that goes far beyond roads and bridges to include core party priorities, from lowering the Medicare eligibility age to 60 and adding dental, vision and hearing benefits to incorporating a long-running effort to provide legal status for certain immigrants, including “Dreamers."

To curb drug prices, Democrats still seeking a balance

WASHINGTON — Democrats are committed to passing legislation this year to curb prescription drug prices, but they're still disagreeing on how to cut costs for patients and taxpayers while preserving profits that lure investors to back potentially promising treatments.

Medicare copays for new Alzheimer’s drug could reach $11,500

 A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Wednesday.

FDA approves much-debated Alzheimer’s drug panned by experts

Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease.